Table 2.
Persistence with lipid lowering drugs 1994–96 in Funen and Bologna in total and in selected strata. Co-prescription with antidiabetic or cardiovascular drugs.
| Funen | Bologna | |||||
|---|---|---|---|---|---|---|
| Persistent | Total | Persistent | Total | |||
| Variable | n | n | % Persistent (95% CI) | n | n | % Persistent (95% CI) |
| Total | 1204 | 1326 | 90,8 (89,1–92,3) | 5870 | 12360 | 47,5 (46,6–48,4) |
| Females | 552 | 604 | 91,4 (88,9–93,5) | 3861 | 7844 | 49,2 (48,1–50,3) |
| Males | 652 | 722 | 90,3 (87,9–92,4) | 2009 | 4616 | 43,5 (42,1–45,0) |
| 0–44 years | 122 | 151 | 80,8 (73,6–86,7) | 200 | 1162 | 17,2 (15,1–19,5) |
| 45–64 years | 750 | 809 | 92,7 (90,7–94,4) | 2356 | 4848 | 48,6 (47,2–50,0) |
| 65–74 years | 298 | 324 | 92,0 (88,5–94,7) | 2618 | 4680 | 55,9 (54,5–57,4) |
| 75 + years | 34 | 42 | 81,0 (65,9–91,4) | 696 | 1670 | 41,7 (39,3–44,1) |
| −Co-prescription | 462 | 524 | 88,2 (85,1–90,8) | 2200 | 5259 | 41,8 (40,5–43,2) |
| + Co-prescription | 742 | 802 | 92,5 (90,5–94,2) | 3670 | 7101 | 51,7 (50,5–52,9) |